Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on October 16, 2020. The filing reports the entry into a material definitive agreement regarding the Company's allogeneic CAR T cell therapy candidate, PBCAR0191.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a contractual amendment.
Material Changes and Agreement Details
On October 16, 2020, the Company entered into Amendment No. 6 to its Development and Commercial License Agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier. Key terms include:
- Scope: The amendment applies solely to PBCAR0191, a therapy targeting CD19 for relapsed or refractory non-Hodgkin lymphoma (NHL) and B-cell precursor acute lymphoblastic leukemia (B-ALL).
- Clinical Trial Obligations: The Company must complete the ongoing Phase 1/2a clinical trial for a specified number of patients in Phase 1 and a number to be determined by the Company in Phase 2a.
- Cost Responsibility: The Company is solely responsible for all costs and expenses to complete the trial, including production and release of clinical trial material.
- Milestones and Options: Trial results will determine if development milestones are achieved, triggering payments from Servier to the Company. Results will also determine Phase 2 readiness, allowing Servier to exercise a commercial option subject to a fee.
- Future Obligations: Upon trial completion, the Company has no further development obligations under the agreement unless mutually agreed otherwise.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the payment of milestone payments and the potential exercise of the commercial option by Servier. Management notes that actual results may differ due to various risks, including:
- Ability to become profitable and procure sufficient funding.
- Success of clinical trials and regulatory approvals.
- Dependence on ARCUS technology and potential for off-target editing or adverse events.
- Competition in the genome editing and biopharmaceutical fields.
- Manufacturing challenges and intellectual property protection.
The Company states it does not plan to publicly update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the specific number of patients required for the Phase 1 portion of the clinical trial as defined in the full text of Amendment No. 6.
- Review the specific dollar amounts associated with development milestone payments and the commercial option exercise fee, which are not detailed in this summary.
- Confirm the current status and enrollment progress of the PBCAR0191 Phase 1/2a clinical trial.
- Assess the Company's cash runway to ensure it can fund the sole responsibility for trial costs without immediate additional financing.
- Monitor future filings for the exercise of Servier's commercial option following the determination of Phase 2 readiness.